Table 3.
Summary of statistical results for the Control, Kangfuxin solution-treated, and PDNN-treated groups
|
|
Control
|
KFX
|
PDNN
|
P value
|
| Weight loss, kg | 4.08 ± 0.69 | 1.98 ± 0.79b | 2.03 ± 1.07b | 0.011 |
| Dysphagia score | 3.50 ± 0.58 | 1.75 ± 0.50b | 1.25 ± 0.96a | 0.004 |
| Esophageal stricture rate | 87.68 ± 1.90 | 59.67 ± 5.05a | 53.90 ± 6.29a | < 0.001 |
| Number of inflammatory cells | 1976.25 ± 116.39 | 950.25 ± 276.92a,e | 1651.50 ± 153.97c | < 0.001 |
| Number of fibroblasts | 5736.25 ± 691.56 | 1537.00 ± 118.89a, f | 710.00 ± 347.14a | < 0.001 |
| Fibrosis area ratio | 66.20 ± 8.95 | 34.63 ± 3.64a,f | 23.47 ± 2.65a | < 0.001 |
| Thickness of submucosal fibrosis, um | 853.93 ± 20.16 | 672.20 ± 28.69a,d | 512.83 ± 42.73a | < 0.001 |
P < 0.001 vs the control group.
P < 0.01 vs the control group.
P < 0.05 vs the control group.
P < 0.001 vs the prednisolone (PDNN) group.
P < 0.01 vs the PDNN group.
P < 0.05 vs the PDNN group.
Data are presented as mean ± SE. KFX: Kangfuxin solution; PDNN: Prednisolone.